Alto Neuroscience, Inc. Schedule 13G/A amendment reports that Point72-related entities and Steven A. Cohen beneficially owned 1,170,865 shares of Common Stock, equal to 3.7% of the class as of the close of business on March 31, 2026.
The filing breaks holdings across affiliates: Point72 Asset Management and Point72 Capital Advisors report 503,087 shares (1.6%), and Point72 Biotech (with related entities) reports 667,778 shares (2.1%). Ownership is reported as shared voting and dispositive power; beneficial ownership is asserted through control relationships and advisory arrangements.
Positive
None.
Negative
None.
Insights
Large asset manager group holds a modest stake in Alto Neuroscience.
Point72 entities and Steven A. Cohen are reported to beneficially own 1,170,865 shares (3.7% of the class) as of March 31, 2026. The filing attributes shares across multiple affiliated entities and notes shared voting and dispositive power.
Impact depends on future disclosure or trading activity by the reporting persons; the statement records ownership and control relationships rather than any transactions or planned actions.
Amendment clarifies attribution and adviser relationships under Section 13 reporting.
The filing names Point72 Asset Management, Point72 Capital Advisors, Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Steven A. Cohen and references sub-advisers relying on Point72's Form ADV. Numbers are reported "as of" the close of business on March 31, 2026.
Filing language preserves customary caution: it states that reporting should not be construed as admission of beneficial ownership for Section 13 purposes.
Key Figures
Total reported shares:1,170,865 sharesTotal percent of class:3.7%Point72 Asset Management holding:503,087 shares+1 more
4 metrics
Total reported shares1,170,865 sharesaggregate beneficial ownership reported as of March 31, 2026
Total percent of class3.7%percent of class reported as of March 31, 2026
Point72 Asset Management holding503,087 sharesreported shared holdings (1.6%) as of March 31, 2026
Point72 Biotech holding667,778 sharesreported shared holdings (2.1%) as of March 31, 2026
Key Terms
beneficially owned, shared dispositive power, Form ADV, Schedule 13G/A
4 terms
beneficially ownedregulatory
"The information required by Item 4(a) is set forth in Row 9 of the cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerregulatory
"Shared Dispositive Power 503,087.00"
Form ADVregulatory
"relying advisers on the Form ADV of Point72 Asset Management"
Schedule 13G/Aregulatory
"This statement is filed by: (i) Point72 Asset Management"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
What stake does Point72/Steven A. Cohen report in ANRO?
They report beneficial ownership of 1,170,865 shares, representing 3.7% of the class as of March 31, 2026. The ownership is allocated across affiliated entities reporting shared voting and dispositive power under control and advisory relationships.
Which Point72 entities hold shares of Alto Neuroscience (ANRO)?
Point72 Asset Management, Point72 Capital Advisors, Inc., Point72 Biotech Private Investments, LLC, Differentiated Ventures, and 72 Investment Holdings are named; some shares are held through a fund managed by Point72 Asset Management and related affiliates.
Are the reported holdings direct or shared ownership?
The filing indicates the reporting persons have shared voting and shared dispositive power over the reported shares. Point72 entities and Mr. Cohen report control relationships and advisory arrangements rather than direct sole ownership of the shares.
What is the effective date for the ownership figures in the ANRO filing?
The ownership figures are reported as of the close of business on March 31, 2026. The Schedule 13G/A amendment incorporates the cover-page rows and cites that date as the time anchor for the share counts and percentages.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Alto Neuroscience, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
02157Q109
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
503,087.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
503,087.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
503,087.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
503,087.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
503,087.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
503,087.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.6 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Point72 Biotech Private Investments, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
667,778.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
667,778.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
667,778.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Differentiated Ventures Investments, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
667,778.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
667,778.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
667,778.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
72 Investment Holdings, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
667,778.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
667,778.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
667,778.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,170,865.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,170,865.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,170,865.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.7 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Alto Neuroscience, Inc.
(b)
Address of issuer's principal executive offices:
650 Castro Street, Suite 450, Mountain View, CA 94041
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Alto Neuroscience, Inc. held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to shares of Common Stock held by an investment fund managed by Point72 Asset Management; (iii) Point72 Biotech Private Investments, LLC ("Point72 Biotech") with respect to shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC ("Differentiated Ventures"), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC ("72 Investment Holdings"), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen ("Mr. Cohen") with respect to shares of Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings.
Each of Cubist Systematic Strategies, LLC, Point72 Asia (Singapore) Pte. Ltd., Point72 (DIFC) Limited, and Point72 Europe (London) LLP are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the shares of Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
02157Q109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.
Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner. Mr. Cohen controls each of Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings.
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)
Percent of class:
3.7%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
